v3.25.3
Revenue Recognition - Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
[1]
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]          
Revenue $ 1,180,534 $ 986,308 $ 3,528,393 $ 2,596,671  
Cost of revenue 678,977 239,247 1,497,110 753,735  
Gross profit 501,557 747,061 $ 2,031,283 1,842,936  
Gross Profit %     57.57%    
Net loss (4,353,741) $ (887,146) $ (6,419,566) $ (4,924,785)  
Assets 4,519,827   4,519,827   $ 3,821,429
Global Stem Cells Group [Member]          
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]          
Revenue     3,528,393    
Cost of revenue     1,497,110    
Gross profit     $ 2,031,283    
Gross Profit %     57.57%    
Net loss     $ (402,871)    
Assets 2,704,271   2,704,271    
Regenerative Medical Technology Group [Member]          
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]          
Revenue        
Cost of revenue        
Gross profit        
Gross Profit %     0.00%    
Net loss     $ (6,016,695)    
Assets $ 1,815,556   $ 1,815,556    
[1] Derived from audited information